Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027230 | 0.83 | HDAC6 (0.34) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL2027231 | 0.83 | HDAC6 (0.34) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL16284723 | 0.81 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL16284720 | 0.81 | HDAC6 (0.36) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL16284721 | 0.78 | CA1 (0.39) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL27822328 | 0.77 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL8341454 | 0.76 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL4329499 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL7996579 | 0.74 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL8000626 | 0.74 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149505-A1 | Metabotropic Glutamate Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149505-A1 | Metabotropic Glutamate Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| WO-2007095024-A1 | METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING ΓSOINDOLONES | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149505-A1 | Metabotropic Glutamate Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM3 | HDAC6 1985/4885HDAC1 2194/4885HDAC2 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.